ReviewWorld journal of gastroenterology2022
Gut microbiota alteration and modulation in hepatitis B virus-related fibrosis and complications: Molecular mechanisms and therapeutic inventions.
Review in World journal of gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Vildagliptin attenuates the development of CCl₄-induced liver fibrosis: associations with gut-liver axis modulation and LPS/notch-related signaling.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Gut-Liver Axis Mechanisms Underlying Spontaneous Reversal of Liver Fibrosis: A Gut Microbiota-Metabolomics Analysis.Metabolites · 2026Article
- Association between hepatitis virus infection and risk of colorectal polyps: a cross-sectional study of Taiwanese adults.BMC gastroenterology · 2026Article
- Insights into the influencing factors of fecal gut microbiota in hepatocellular carcinoma.World journal of gastroenterology · 2026Article
- Serum type III procollagen, procollagen V, tumour necrosis factor-a, interleukin-6 in liver cirrhosis after antiviral treatment.Journal of medical biochemistry · 2025Article
- Relationship between gut microbiota dysbiosis and bile acid in patients with hepatitis B-induced cirrhosis.BMC gastroenterology · 2025Article
- Microbial Approaches to Treat and Prevent Hepatic Encephalopathy.Gastroenterology clinics of North America · 2025Review
- Construction and validation of a nomogram prediction model for antiviral efficacy based on clinical characteristics and intestinal microflora distribution in patients with chronic hepatitis B.Frontiers in medicine · 2025Article
- Gut-liver-muscle axis: linking gut microbiota dysbiosis to malnutrition and sarcopenia in liver disease.Frontiers in medicine · 2025Review
- Gut microbiota dysbiosis in diabetic nephropathy: mechanisms and therapeutic targeting via the gut-kidney axis.Frontiers in endocrinology · 2025Review
- Portocaval shunts' role in gut microbiota and hepatic encephalopathy: The gut-to-brain pathway.World journal of gastroenterology · 2024Article
- Microbiome Dynamics: A Paradigm Shift in Combatting Infectious Diseases.Journal of personalized medicine · 2024Review
- Sini san regulates intestinal flora and short-chain fatty acids to ameliorate hepatocyte apoptosis and relieve CClFrontiers in pharmacology · 2024Article
- Probiotic management and inflammatory factors as a novel treatment in cirrhosis: A systematic review and meta-analysis.Open life sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis B virus (HBV) has posed a threat to public health, mainly resulting in liver damage. With long-term accumulation of extracellular matrix, patients with chronic hepatitis B are at high risk of developing into liver fibrosis and cirrhosis and even life-threatening hepatic carcinoma. The occurrence of complications such as spontaneous bacterial peritonitis and hepatic encephalopathy greatly increases disability and mortality. With deeper understanding of the bidirectional interaction between the liver and the gut (gut-liver axis), there is a growing consensus that the human health closely relates to the gut microbiota. Supported by animal and human studies, the gut microbiota alters as the HBV-related liver fibrosis initials and progresses, characterized as the decrease of the ratio between "good" and "potentially pathogenic" microbes. When the primary disease is controlled
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.